Home LiteratureArticle Details
PMID: 25830880 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

The evolutionary history of lethal metastatic prostate cancer.

Nature ·Vol. 520 ·No. 7547 ·2015-04-16 ·Pages 353-357

Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, ICGC Prostate Group, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS

Abstract

Cancers emerge from an ongoing Darwinian evolutionary process, often leading to multiple competing subclones within a single primary tumour. This evolutionary process culminates in the formation of metastases, which is the cause of 90% of cancer-related deaths. However, despite its clinical importance, little is known about the principles governing the dissemination of cancer cells to distant organs. Although the hypothesis that each metastasis originates from a single tumour cell is generally supported, recent studies using mouse models of cancer demonstrated the existence of polyclonal seeding from and interclonal cooperation between multiple subclones. Here we sought definitive evidence for the existence of polyclonal seeding in human malignancy and to establish the clonal relationship among different metastases in the context of androgen-deprived metastatic prostate cancer. Using whole-genome sequencing, we characterized multiple metastases arising from prostate tumours in ten patients. Integrated analyses of subclonal architecture revealed the patterns of metastatic spread in unprecedented detail. Metastasis-to-metastasis spread was found to be common, either through de novo monoclonal seeding of daughter metastases or, in five cases, through the transfer of multiple tumour clones between metastatic sites. Lesions affecting tumour suppressor genes usually occur as single events, whereas mutations in genes involved in androgen receptor signalling commonly involve multiple, convergent events in different metastases. Our results elucidate in detail the complex patterns of metastatic spread and further our understanding of the development of resistance to androgen-deprivation therapy in prostate cancer.

MeSH Terms
Androgens/deficiency Cell Lineage/genetics Clone Cells/metabolism,pathology DNA Mutational Analysis Disease Progression Epigenesis, Genetic Genes, Tumor Suppressor Humans Male Neoplasm Metastasis/genetics,pathology Prostatic Neoplasms/genetics,metabolism,pathology Receptors, Androgen/metabolism Signal Transduction/genetics
Chemicals
Androgens Receptors, Androgen
Authors & Affiliations
31 authors, click to expand affiliations / ORCID
Gundem Gunes
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Van Loo Peter
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK. | Department of Human Genetics, KU Leuven, Herestraat 49 Box 602, B-3000 Leuven, Belgium. | Cancer Research UK London Research Institute, London, UK.
Kremeyer Barbara
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Alexandrov Ludmil B
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Tubio Jose M C
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Papaemmanuil Elli
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Brewer Daniel S
Norwich Medical School and Department of Biological Sciences, University of East Anglia, Norwich, UK.
Kallio Heini M L
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
Högnäs Gunilla
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
Annala Matti
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
Kivinummi Kati
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
Goody Victoria
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Latimer Calli
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
O'Meara Sarah
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Dawson Kevin J
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Isaacs William
The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Emmert-Buck Michael R
Laboratory of Pathology, National Cancer Institute, National Institutes of Health, MD, USA.
Nykter Matti
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
Foster Christopher
University of Liverpool and HCA Pathology Laboratories, London, UK. | Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project.
Kote-Jarai Zsofia
Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK.
Easton Douglas
Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK. | Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project.
Whitaker Hayley C
Uro-oncology Research Group, Cancer Research UK Cambridge Research Institute, Cambridge, UK.
ICGC Prostate Group
Neal David E
Uro-oncology Research Group, Cancer Research UK Cambridge Research Institute, Cambridge, UK. | Department of Surgical Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. | Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project.
Cooper Colin S
Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK. | Norwich Medical School and Department of Biological Sciences, University of East Anglia, Norwich, UK. | Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project.
Eeles Rosalind A
Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK. | Royal Marsden NHS Foundation Trust, London and Sutton, UK. | Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project.
Visakorpi Tapio
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
Campbell Peter J
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
McDermott Ultan
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK. | Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project.
Wedge David C
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Bova G Steven
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland. | Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project.
Investigators
62 investigators, click to expand
Cooper Colin S
Eeles Rosalind A
Bova G Steven
Easton Douglas
Foster Christopher
Futreal Andrew
McDermott Ultan
Neal David E
Stratton Michael
Brewer Daniel S
Butler Adam P
Gundem Gunes
Hamdy Freddie
Lu Yong-Jie
Lynch Andrew G
Massie Charlie E
Ng Anthony
Van Loo Peter
Wedge David C
Whitaker Hayley C
Yu Yongwei
Zhang Hongwei
Alexandrov Ludmil B
Bancroft Elizabeth
Berney Dan
Camacho Niedzica
Corbishley Cathy
Dadaev Tokhir
Dennis Nening
Dudderidge Tim
Edwards Sandra
Fisher Cyril
Ghori Jilur
Gnanapragasam Vincent J
Greenman Christopher
Hawkins Steve
Hazell Steven
Howat Will
Karaszi Katalin
Kay Jonathan
Kote-Jarai Zsofia
Kremeyer Barbara
Kumar Pardeep
Lambert Adam
Leongamornlert Daniel
Livni Naomi
Luxton Hayley
Matthews Lucy
Mayer Erik
Merson Susan
Nicol David
Ogden Christopher
O'Meara Sarah
Pelvender Gill
Radcliffe John
Shah Nimish C
Tavare Simon
Thomas Sarah
Thompson Alan
Verrill Claire
Warren Anne
Zamora Jorge
References (25)
25 references, click to expand
  1. A molecular signature of metastasis in primary solid tumors.
    Nat Genet. 2003 Jan;33(1):49-54 PMID: 12469122
  2. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity.
    Nature. 2014 Oct 2;514(7520):54-8 PMID: 25079331
  3. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited.
    Nat Rev Cancer. 2003 Jun;3(6):453-8 PMID: 12778135
  4. Myc confers androgen-independent prostate cancer cell growth.
    J Clin Invest. 2003 Dec;112(11):1724-31 PMID: 14660748
  5. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus.
    Cancer Res. 2004 May 15;64(10):3414-27 PMID: 15150093
  6. A gene expression signature associated with metastatic outcome in human leiomyosarcomas.
    Cancer Res. 2004 Oct 15;64(20):7201-4 PMID: 15492233
  7. The clonal evolution of tumor cell populations.
    Science. 1976 Oct 1;194(4260):23-8 PMID: 959840
  8. The pathogenesis of cancer metastasis.
    Nature. 1980 Jan 10;283(5743):139-46 PMID: 6985715
  9. In vivo amplification of the androgen receptor gene and progression of human prostate cancer.
    Nat Genet. 1995 Apr;9(4):401-6 PMID: 7795646
  10. Cancer metastasis: building a framework.
    Cell. 2006 Nov 17;127(4):679-95 PMID: 17110329
  11. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.
    Cancer Cell. 2008 Aug 12;14(2):146-55 PMID: 18691549
  12. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.
    Nat Clin Pract Urol. 2009 Feb;6(2):76-85 PMID: 19198621
  13. AACR centennial series: the biology of cancer metastasis: historical perspective.
    Cancer Res. 2010 Jul 15;70(14):5649-69 PMID: 20610625
  14. The patterns and dynamics of genomic instability in metastatic pancreatic cancer.
    Nature. 2010 Oct 28;467(7319):1109-13 PMID: 20981101
  15. Distant metastasis occurs late during the genetic evolution of pancreatic cancer.
    Nature. 2010 Oct 28;467(7319):1114-7 PMID: 20981102
  16. Clonal evolution in cancer.
    Nature. 2012 Jan 19;481(7381):306-13 PMID: 22258609
  17. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
    N Engl J Med. 2012 Mar 8;366(10):883-92 PMID: 22397650
  18. The life history of 21 breast cancers.
    Cell. 2012 May 25;149(5):994-1007 PMID: 22608083
  19. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.
    Nat Med. 2012 Sep;18(9):1359-68 PMID: 22863786
  20. β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma.
    PLoS Genet. 2013;9(1):e1003180 PMID: 23300485
  21. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.
    Cancer Cell. 2013 Jan 14;23(1):35-47 PMID: 23260764
  22. GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer.
    Cancer Cell. 2013 Jul 8;24(1):11-3 PMID: 23845440
  23. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
    Nat Commun. 2014;5:2997 PMID: 24429703
  24. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing.
    Cell. 2014 Mar 13;156(6):1298-311 PMID: 24630729
  25. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers.
    Nature. 2014 Apr 3;508(7494):113-7 PMID: 24695311
Article Info
Journal
Nature
Abbr.
Nature
ISSN
1476-4687
Published
2015-04-16
Epub
2015-00-01
Pages
353-357
Language
English
Region
England
NLM ID
0410462
PMCID
PMC4413032
Subset
IM
Grants
NCI NIH HHS · R01 CA092234 · United States
Intramural NIH HHS · United States
NCI NIH HHS · CA92234 · United States
Cancer Research UK · A14835 · United Kingdom
Cancer Research UK · A12758 · United Kingdom
Wellcome Trust · 077012 · United Kingdom
Corrections
CommentIn
CommentIn
CommentIn
ErratumIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com